HLX05 (cetuximab biosimilar) / Fosun Pharma, Jingze Biotech 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HLX05 (cetuximab biosimilar) / Fosun Pharma, Jingze Biotech
NCT06309043: A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects

Active, not recruiting
1
268
RoW
recombinant anti-EGFR human/murine chimeric monoclonal antibody injection
Shanghai Henlius Biotech
EGFR Overexpression
06/26
12/26

Download Options